Welcome to Foundation Medicine

Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue. View our Privacy Policy to learn more.
×
Menu
Close
Our portfolioFoundationOne® CDxFoundationOne® Liquid CDx

 

 

Our portfolio of genomic profiling services

High-quality portfolio

Foundation Medicine: An established portfolio of services for patients across diverse clinical situations

Foundation Medicine’s established portfolio of comprehensive genomic profiling (CGP) services should be used to inform the use of immunotherapies, identify alternative therapy options or identify trial opportunities:1–7
EXPLORE EXPLORE Solid tumour What type of tumour does your patient have? Tissue sample Blood sample T i s s u e - b a s e d t e s t f o r s o l i d t u m o u r s 8 L i q u i d b i o p s y t e s t f o r s o l i d t u m o u r s 7 , 9
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine’s services use our CGP approach, which analyses the tumour genome to identify clinically relevant alterations and inform treatment decision-making.1–7
Learn more about CGP
Genomic database

 

Our tests evolve as our understanding of cancer broadens

Our continuously growing genomic database currently includes over 400,000 genomic profiles across numerous tumour subtypes.10 Advanced bioinformatics interrogate the data, including fields not currently reported clinically (such as loss of heterozygosity), to generate potentially actionable insights.10

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights

M-GB-00001595 September 2020

*Based on typical turnaround time of <2 weeks from receipt of sample.

FFPE: formalin-fixed paraffin embedded.

M-GB-00001595 September 2020

References

  1. Frampton GM et al. Nat Biotechnol 2013;31:1023–1031.
  2. Drilon A et al. Clin Cancer Res 2015;21:3631–3639.
  3. Rankin A et al. Oncologist 2016;21:1306–1314.
  4. Ross JS et al. Cancer 2016;122:2654–2662.
  5. Suh JH et al. Oncologist 2016;21:684–691.
  6. Hirshfield KM et al. Oncologist 2016;21:1315–1325.
  7. Woodhouse R, et al. PLoS One. 2020;15:e-237802.
  8. FoundationOne® CDx Technical Specifications M-GB-00001548 September 2020
  9. FoundationOne® Liquid CDx Technical Specifications M-GB-00000169 September 2020.
  10. FoundationCore™. FoundationInsights™. Available at https://www.foundationmedicine.com/insights-and-trials/foundation-insights. Last accessed September 2020.